Abstract:Hundreds of millions of SARS-CoV-2 mRNA-LNP vaccine doses have already been administered to humans. However, we lack a comprehensive understanding of the immune effects of this platform. The mRNA-LNP-based SARS-CoV-2 vaccine is highly inflammatory, and its synthetic ionizable lipid component responsible for the induction of inflammation has a long in vivo half-life. Since chronic inflammation can lead to immune exhaustion and non-responsiveness, we sought to determine the effects of pre-exposure to the mRNA-LNP on adaptive immune responses and innate immune fitness. We found that pre-exposure to mRNA-LNPs or LNP alone led to long-term inhibition of the adaptive immune response, which could be overcome using standard adjuvants. On the other hand, we report that after pre-exposure to mRNA-LNPs, the resistance of mice to heterologous infections with influenza virus increased while resistance to Candida albicans decreased. The diminished resistance to Candida albicans correlated with a general decrease in blood neutrophil percentages. Interestingly, mice pre-exposed to the mRNA-LNP platform can pass down the acquired immune traits to their offspring, providing better protection against influenza. In summary, the mRNA-LNP vaccine platform induces long-term unexpected immunological changes affecting both adaptive immune responses and heterologous protection against infections. Thus, our studies highlight the need for more research to determine this platform's true impact on human health. We bring experimental evidence that pre-exposure to mRNA-LNPs or its LNP component affects innate and adaptive immune responses. Pre-exposure to mRNA-LNPs led to long-term inhibition of the adaptive immune responses, which the use of adjuvants could overcome. On the other hand, we report that after pre-exposure to mRNA-LNPs, the resistance of mice to heterologous infections with influenza virus increased, while resistance to Candida albicans decreased. We also detected a general neutropenia in the mRNA-LNP exposed mice. Interestingly, mice pre-exposed to mRNA-LNPs can pass down the acquired immune traits to their offspring. In summary, the mRNA-LNP vaccine platform induces long-term immunological changes that can affect both adaptive immune responses and heterologous protection against infections, some of which can be inherited by the offspring. More studies are needed to understand the mechanisms responsible for these effects and determine this platform's impact on human health.

mRNA Vaccine Nanoplatforms and Innate Immunity

Structural and biochemical characteristics of mRNA nanoparticles determine anti-SARS-CoV-2 humoral and cellular immune responses

Innate immune mechanisms of mRNA vaccines

Mrna Vaccines Contribute to Innate and Adaptive Immunity to Enhance Immune Response in Vivo

Nanotechnology-based mRNA vaccines

mRNA Vaccination: An Outlook on Innate Sensing and Adaptive Immune Responses

Nanoparticle Technology for Mrna: Delivery Strategy, Clinical Application and Developmental Landscape

The Immunostimulatory Nature of mRNA Lipid Nanoparticles

Innate and Adaptive Immune Parameters following mRNA Vaccination in Mice

mRNA vaccine designs for optimal adjuvanticity and delivery

Advancing mRNA Therapeutics: The Role and Future of Nanoparticle Delivery Systems

Progress and Challenges of Mrna Vaccines

An Overview of Nanoparticle-Based Delivery Platforms for Vaccines

Recent Advances in Biomaterials for mRNA Delivery to Immune Cells

The landscape of mRNA nanomedicine

An Overview of Nanoparticle-Based Delivery Platforms for mRNA Vaccines for Treating Cancer

The nano delivery systems and applications of mRNA

Pre-exposure to mRNA-LNP inhibits adaptive immune responses and alters innate immune fitness in an inheritable fashion

Progress on Mrna Vaccines and Lipid Nanoparticles

Enhancing Vaccine Efficacy and Stability: A Review of the Utilization of Nanoparticles in mRNA Vaccines

A Comprehensive Review of mRNA Vaccines